Argus keeps a Hold rating on Clorox while noting that the firm is looking for a more favorable entry point on the stock. The benefit from increased sales during the pandemic’s demand for cleansing products spiked has subsided, and inflation has put sales and margins under pressure, but the firm has a favorable view of the company’s IGNITE strategy, which aims to accelerate innovation in key areas of the business and integrate ESG priorities into decision-making, the analyst tells investors in a research note. If input prices moderate or demand for Clorox products accelerates, the firm would consider adding the stock to its Buy list, Argus added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Rising Digital Threats Make CyberArk Software Stock (NASDAQ:CYBR) Almost a No-Brainer
- Clorox price target lowered to $135 from $140 at Wells Fargo
- Clorox price target lowered to $132 from $136 at Barclays
- Clorox price target lowered to $150 from $155 at Citi
- Clorox reports Q3 gross margin up 40 bps to 42.2% from 41.8% last year